Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05646056 · ClinicalTrials.gov registry record
A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
A clinical trial, sponsored by Prolaio.
- Completed
- Registry status
- 82
- Enrollment target
NCT05646056: Completed study, sponsored by Prolaio.
NCT05646056 is a clinical trial that has completed, run by Prolaio. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05646056 has completed, sponsored by Prolaio.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
This is a non-invasive/observational study in healthy and mild HF subjects utilizing clinical and ambulatory measurements to improve detection, monitoring, and management of HF risks.
Primary Outcome
Percentage of complete daily datasets transmitted to the Pyxida System database at the end of the monitoring period
Interventions
- DEVICE Software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-10-28 |
| Est. Completion | 2024-09-18 |
What the finished NCT05646056 record still lists
NCT05646056 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Software is the first listed.
NCT05646056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05646056 about?
NCT05646056 is a clinical study titled "A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk". This is a non-invasive/observational study in healthy and mild HF subjects utilizing clinical and ambulatory measurements to improve detection, monitoring, and management of HF risks.
What is the current status of trial NCT05646056?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2022-10-28. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT05646056?
The interventions under investigation include: Software (DEVICE).
Who is sponsoring clinical trial NCT05646056?
This trial is sponsored by Prolaio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI